Abstract # O-130

20th Conference on Retroviruses and Opportunistic Infections Atlanta, GA, USA

Performance of Determine™ HIV-1/2 Ag/Ab Combo Test to Detect Acute Infections in a High-Prevalence Cross-Sectional Population in Swaziland

Yen T. Duong¹, Yvonne Mavengere², Julius Manjengwa², Dumile Sibandze³, Joy Chang¹, Lynda Marie Emel⁴, Jessica Justman², Jason Reed¹, George Bicego⁵, Bharat S. Parekh¹ and SHIMS Study Team

¹Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, USA, ²International Center for AIDS Care and Treatment (ICAP), Columbia University, New York, NY, USA, ³Ministry of Health, Swaziland, ⁴Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Fred Hutchison Cancer Research Center, Seattle, Washington, USA, ⁵Centers for Disease Control and Prevention, Mbabane, Swaziland

Yen T. Duong 1600 Clifton Rd Atlanta, GA 30333 yduong@cdc.gov (404) 639-1406

BACKGROUND

Fourth-generation HIV rapid tests (RTs) incorporate p24 antigen detection for early identification of acute infections. Inclusion of p24 detection in a diagnostic rapid test may allow for a decrease in the diagnostic window period. Identification of acute HIV infections may be an important approach in preventing HIV transmission and reducing HIV incidence.

METHODS

As a part of the Swaziland HIV Incidence Measurement Survey (SHIMS):

- 18,154 individuals were household tested for HIV infection using a two-RT serial algorithm; Determine™ HIV-1/2 Ag/Ab Combo followed by UniGold™ as the confirmatory RT (Figure 1).
- Discordant samples were resolved by tiebreaker EIAs. Determine Ag+ only samples were further tested for viral load using Roche CAPTAQ HIV-1 Test, V2.0.
- All RT non-reactive samples had nucleic acid amplification testing (NAAT) performed in plasma pools of 10 to identify true acute infections.
- Determine[™] Combo Ag+/Ab- and NAAT-positive acute cases had followup testing to confirm seroconversion.

Baseline Incidence Cohort 1 T1 T2 NAT (HIV-) HIV Prevention and Treatment Campaign LEGEND Longitudinal Cohort 18-49 year old men and women HIV testing

RESULTS


Of 18,154 whole blood specimens tested:

- Determine™ Combo and of those, 5784 confirmed reactive by Unigold (99.4% agreement)
- Identified 12 Ag+/Ab- samples by Determine[™] Combo - all VL negative and therefore were not confirmed acute infections
- Of the 12 individuals with Ag+/Abresults, 8 had a 6-week follow-up visit and were found to be HIVnegative

Plasma pooling on the 12,325 Ag-/Ab- non-reactive Determine™ Combo specimens revealed:

- 13 NAAT-pos specimens with HIV RNA values ranging from 300 to >10,000,000 copies/mL
- Repeat HIV serology 13 NAAT-pos specimens confirmed all Ag and Ab non-reactive
- Follow-up testing of 12 of the 13 NAAT-pos individuals at 6 months showed 12 seroconversions (1 case lost to follow-up)
- Determine[™] Combo had a sensitivity of 0% (95% CI 0%-25%) and positive predictive value of 0% for detection of acute infections

HIV TESTING RESULTS



CONCLUSIONS

The ability of Determine™ Combo to detect HIV antibodies was excellent but the sensitivity to detect antigen was extremely poor. Thus, Determine™ Combo RT should not be used in this population to detect acute infections because it does not add any value to the current testing algorithm, rather it adds unnecessary costs and complexity.







